Patient status (WHO scale)
The WHO clinical progression scale progressively decreased in all treatment groups during the study. At V1, a comparable distribution of patients with a score of 1 (14.8% in the 0.1% azelastine group, 14.3% in the 0.02% azelastine group and 23.1% in the placebo group) or 2 (85.2% in the 0.1% azelastine group, 85.7% in the 0.02% azelastine group and 76.9% in the placebo group) was observed. At the end of the study (day 60), all except one single patient (placebo group) showed a score of 0.